Patient-derived organoids (PDOs) established from metastatic and circulating tumor cells can retain the histological and molecular features of the patient tumors and recapitulate the diversity of clinical PCa subtypes, including TMPRSS2-ERG fusion, SPOP mutations, TP53 loss, PTEN loss and CHD1 loss [13]. The gene discussed is SPOP; the disease is posterior cortical atrophy.